A genetic variant is associated with toxicity of the chemotherapy drug melphalan, and could guide individualized dosing for the medication.

The nuclear receptor TR3 contributes to ovarian cancer cell death in response to platinum-based chemotherapy – and may be a good target for overcoming cell resistance to certain treatments.

Researchers are developing imaging methods to predict patient outcome early in the course of chemotherapy for breast cancer – to allow clinicians to adjust therapy for patients who are not responding.

Combining another drug with platinum-based chemotherapies may be more effective against ovarian cancer.

A study led by Vanderbilt-Ingram Cancer Center investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn’t effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer.

Patients and their families will have a more active role and voice in research designed to improve the quality and safety of patient care, thanks to a federal grant received by Vanderbilt University Medical Center researchers.